4-(Prop-2-en-1-yl)piperidin-4-ol

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(Prop-2-en-1-yl)piperidin-4-ol
• 英文别名: 4-prop-2-enylpiperidin-4-ol
• 化学式: C₈H₁₅NO
• mdl: MFCD05259621
• 分子量: 141.21
• InChiKey: BYWHWKOPJSTPIT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• 4-alkyl piperidinyl pyrrolidine modulators of chemokine receptor activity
  申请人：——

  公开号：US20020013348A1

  公开（公告）日：2002-01-31

  The present invention is directed to pyrrolidine compounds of the formula I: 1 (wherein R 1 , R 2 , R 3 , R 4c , R 4d , and R 4f are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptors CCR-3 and/or CCR-5.

  本发明涉及公式I:1中的吡咯烷化合物（其中R1、R2、R3、R4c、R4d和R4f在此处定义），这些化合物可用作化学因子受体活性的调节剂。具体来说，这些化合物可用作化学因子受体CCR-3和/或CCR-5的调节剂。
• Enzyme modulators and treatments
  申请人：Flynn L. Daniel

  公开号：US20070078121A1

  公开（公告）日：2007-04-05

  Novel compounds and methods of using those compounds for the treatment of inflammatory conditions, immunological disorders, hyperproliferative diseases, cancer, and diseases characterized by hyper-vascularization are provided. In a preferred embodiment, modulation of the activation state of kinases, including p38 kinase protein, abl kinase protein, bcr-abl kinase protein, braf kinase protein, VEGFR kinase protein, or PDGFR kinase protein, comprises the step of contacting said kinase protein with the novel compounds.

  提供了新型化合物及其使用方法，用于治疗炎症性疾病、免疫性疾病、过度增生性疾病、癌症以及以高血管化为特征的疾病。在一种优选实施方式中，调节激酶的激活状态，包括p38激酶蛋白、abl激酶蛋白、bcr-abl激酶蛋白、braf激酶蛋白、VEGFR激酶蛋白或PDGFR激酶蛋白，包括将该激酶蛋白与新型化合物接触的步骤。
• ENZYME MODULATORS AND TREATMENTS
  申请人：Flynn L. Daniel

  公开号：US20080113967A1

  公开（公告）日：2008-05-15

  Novel compounds and methods of using those compounds for the treatment of inflammatory conditions, hyperproliferative diseases, cancer, and diseases characterized by hyper-vascularization are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein, abl kinase protein, ber-abl kinase protein, braf kinase protein, VEGFR kinase protein, or PDGFR kinase protein comprises the step of contacting said kinase protein with the novel compounds.

  本发明提供了新的化合物及其使用方法，用于治疗炎症状况、过度增殖性疾病、癌症和以高血管化为特征的疾病。在优选实施例中，调节p38激酶蛋白、abl激酶蛋白、ber-abl激酶蛋白、braf激酶蛋白、VEGFR激酶蛋白或PDGFR激酶蛋白的激活状态，包括将该激酶蛋白与新的化合物接触的步骤。
• TRITERPENOIDS WITH HIV MATURATION INHIBITORY ACTIVITY
  申请人：VIIV Healthcare UK(No.4) Limited

  公开号：EP3750910A1

  公开（公告）日：2020-12-16

  Combinations of a compound according to formula Ia and an AIDS antiviral, immunomodulator, HIV entry inhibitor, anti-infective or vaccine. These combinations can be used in the treatment of HIV.

  根据式 Ia 的化合物与艾滋病抗病毒药、免疫调节剂、HIV 进入抑制剂、抗感染药或疫苗的组合物。这些组合物可用于治疗艾滋病毒。
• THERAPEUTIC COMPOUNDS AND COMPOSITIONS
  申请人：Agios Pharmaceuticals, Inc.

  公开号：EP2970189B1

  公开（公告）日：2020-05-06